Immunis, Inc.
PrivateLast Round
Grant
May 12, 2025
Total Funding Raised
$35.25M
Company Overview
Immunis, Inc. is a private, clinical-stage biotechnology company based in Irvine, California, founded in 2019. The company develops multi-active biologics derived from stem cells, known as secretomes, to address age-related diseases and immune dysfunction. Its primary focus is on combating conditions like muscle atrophy (sarcopenia) and metabolic decline. The company's lead investigational therapy, IMM01-STEM, has completed a Phase 1/2a clinical trial and is advancing to Phase 2 studies for sarcopenic obesity. Immunis is venture-backed, having raised capital through multiple financing rounds, including a $25 million Series A-1 in 2025, to fund its clinical research and development.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts, Hardware Sales
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunis, Inc. Comps
Public and private peers based on sector, stage, and business model.
Immunis, Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | May 12, 2025 | ||||
| Series A Extension | Jan 11, 2025 | ||||
| Series A | Aug 3, 2022 |
Immunis, Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Remiges Ventures | Series A Extension, Series A |
| BOLD Capital Partners | Series A Extension |
| X PRIZE Foundation | Grant |
| Continuum Health Ventures | Series A Extension, Series A |
| LifeSpan Vision Ventures | Series A Extension |
| JLS Fund | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 5, 2026
Obtained exclusive rights for product KORA in US, Canada, EU, and EFTA.
- Mar 5, 2026
Continuing development of product IMM02-KORA, also known as KORA.
Immunis, Inc. Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Immunis, Inc.'s valuation, stock price, and market status.
